BioPharma

BioNTech and Gilead Partner for Pumitamig Clinical Trial

Yuvraj — Fri, 23 Oct 2026 13:03:30 +0000

BioNTech SE has officially entered into a clinical trial collaboration and supply agreement with Gilead Sciences Inc. to evaluate the bispecific immunomodulator pumitamig in combination with the TROP2-directed antibody-drug conjugate (ADC) sacituzumab govitecan. Announced on October 22, 2026, this strategic partnership aims to improve therapeutic outcomes for patients diagnosed with locally advanced or metastatic triple-negative […]

The post BioNTech and Gilead Partner for Pumitamig Clinical Trial first appeared on World Pharma Today.

$1.8 Billion Commitment to Centralize Biological Data

Yuvraj — Thu, 08 Oct 2026 13:28:21 +0000

The United States government, alongside technology enterprises Meta Platforms and Alphabet, is officially joining forces with the nonprofit organization Biohub. This collaborative effort aims to construct comprehensive open datasets designed to train advanced AI models for biological research, elevating the total investment in this initiative to $1.8 billion. Financial Contributions and Strategic Partnerships In a […]

The post $1.8 Billion Commitment to Centralize Biological Data first appeared on World Pharma Today.

Large Molecule Development Supporting Complex Biologic Drug Programs

Yuvraj — Mon, 31 Aug 2026 08:07:24 +0000

The pharmaceutical industry is experiencing a profound expansion in the biologic sector, driven by the need for more targeted and effective therapies for chronic diseases. Unlike small molecules, biologics are produced in living systems, which introduces a high degree of complexity in both discovery and manufacturing. This complexity necessitates a rigorous approach to large molecule […]

The post Large Molecule Development Supporting Complex Biologic Drug Programs first appeared on World Pharma Today.

McKesson to Acquire Precision Medicine Group for $2.25 Billion

Yuvraj — Thu, 27 Aug 2026 08:36:00 +0000

US-based healthcare services provider McKesson has agreed to acquire Precision Medicine Group for $2.25 billion, a move aimed at strengthening its clinical research and biopharmaceutical commercialisation services. The McKesson acquisition remains subject to customary closing conditions, including regulatory approvals. Once the transaction receives final clearances, Precision Medicine Group will operate within McKesson’s oncology and multi-speciality […]

The post McKesson to Acquire Precision Medicine Group for $2.25 Billion first appeared on World Pharma Today.

Biopharmaceutical Fluid Handling Systems Improving Process Efficiency and Product Integrity

Yuvraj — Tue, 25 Aug 2026 13:11:32 +0000

The implementation of biopharmaceutical fluid handling systems improving process efficiency and Product Integrity is a foundational requirement for the modern manufacturing of biologics, vaccines, and advanced therapy medicinal products. Unlike traditional chemical synthesis, biopharmaceutical production involves the management of living cells and highly sensitive protein structures that are susceptible to environmental changes and mechanical stress. […]

The post Biopharmaceutical Fluid Handling Systems Improving Process Efficiency and Product Integrity first appeared on World Pharma Today.

Targeted Delivery Systems Improving Pharmacological Agent Localization

Yuvraj — Mon, 24 Aug 2026 12:35:52 +0000

Precision in the delivery of therapeutic compounds remains a primary objective for pharmaceutical scientists seeking to maximize efficacy while minimizing the potential for systemic toxicity. The development of targeted delivery systems improving pharmacological agent localization represents a significant shift in how pharmacological interventions are administered, moving away from broad-spectrum systemic exposure toward highly localized cellular […]

The post Targeted Delivery Systems Improving Pharmacological Agent Localization first appeared on World Pharma Today.

Lipid Nanoparticle Screening Advancing Oligonucleotide Delivery

Yuvraj — Mon, 24 Aug 2026 12:28:37 +0000

The recent success of ribonucleic acid therapeutics has been largely dependent on the development of effective vehicles capable of protecting fragile genetic material from enzymatic degradation while facilitating its entry into target cells. The process of lipid nanoparticle screening advancing oligonucleotide delivery has emerged as a cornerstone of this technological evolution, allowing researchers to systematically […]

The post Lipid Nanoparticle Screening Advancing Oligonucleotide Delivery first appeared on World Pharma Today.

Data Analytics Improving Bioperformance Prediction for Small Molecules

Yuvraj — Mon, 24 Aug 2026 12:20:23 +0000

Pharmaceutical developers are increasingly integrating advanced computational frameworks to address the high rates of attrition in clinical trials, specifically by refining how candidate molecules interact with biological systems. The current shift toward data analytics improving bioperformance prediction for small molecules allows researchers to simulate human physiological responses with unprecedented precision, moving beyond the limitations of […]

The post Data Analytics Improving Bioperformance Prediction for Small Molecules first appeared on World Pharma Today.

Lonza Launches Rapid Media Prototyping Service to Accelerate Biopharmaceutical Development

Yuvraj — Wed, 19 Aug 2026 13:38:24 +0000

Lonza has announced the launch of its Rapid Media Prototyping Service (RaMP) — a solution designed to give biopharmaceutical companies faster access to custom liquid and powder media for screening, process confirmation, and early development. Delivering Speed and Flexibility in Early Development The new service enables the production of non-GMP powder batches ranging from 1 […]

The post Lonza Launches Rapid Media Prototyping Service to Accelerate Biopharmaceutical Development first appeared on World Pharma Today.

Sandoz Expands Global Pipeline with Multi-Product Biosimilar Agreement

Yuvraj — Mon, 17 Aug 2026 14:11:23 +0000

Sandoz has entered into a collaboration agreement with Shanghai Henlius Biotech to co-develop a series of new biosimilars across international markets. The milestone-based transaction carries a total consideration of up to $322m, including near-term payments of up to $100.5m associated with initial product candidates. Under the terms of this biosimilar collaboration, Henlius will oversee development […]

The post Sandoz Expands Global Pipeline with Multi-Product Biosimilar Agreement first appeared on World Pharma Today.